News

The insider still retains significant holdings, valued at $8.5 million, despite the sale.

Hims & Hers Health has been hit with an FTC complaint and multiple securities class action lawsuits alleging improper sharing of sensitive health data and misleading billing practices, events that have already drawn regulatory scrutiny and legal pressure by mid‑2026. The allegations cut to the core of Hims & Hers’ telehealth model, putting its privacy assurances and subscription-based business practices under a spotlight that could reshape how it operates. Against this backdrop of FTC action...

In the most recent trading session, Hims & Hers Health, Inc. (HIMS) closed at $27.93, indicating a -3.07% shift from the previous trading day.

Hims & Hers Health (NYSE:HIMS) shares fell 3.2% after the FDA warned telehealth companies and compounding pharmacies over unapproved weight-loss drugs, including versions of semaglutide, tirzepatide and retatrutide. The agency said retatrutide and cagrilintide cannot legally be used in...

Wobbly start predicted Stock futures wobbled on Tuesday morning as investors weighed the fallout from the weekend's escalation in Iran, a jittery bond market and the growing chance the Fed might hike rates again. Dow and S&P 500 futures slipped around 0.5%, while Nasdaq-100 contracts...

Its deepest fall inside a market shock is not its deepest fall, and that gap is what a holder should size for.

Hims & Hers Shares Sink as Visa Targets Credit Card Disputes

Hims & Hers Health (NYSE:HIMS) is facing a new consumer class action lawsuit alleging misrepresentation of user privacy and unauthorized sharing of sensitive health data. The lawsuit follows a recent FTC civil enforcement action against the company that raised similar concerns about handling of consumer health information. Plaintiffs claim the company misled users about how their health data would be used and shared, potentially affecting customer trust and future regulatory scrutiny. As...

Andrew Dudum told CNBC the agency wanted "more of a headline than a real agreement" after years of cooperative talks

HIMS posts a wider-than-expected loss and weaker gross margin in second-quarter 2026 despite strong revenue growth and a raised full-year outlook.

The telehealth company reported a second-quarter net loss of $86.3 million versus prior-year net income of $42.5 million.

Hims & Hers Health shares are down after the telehealth firm reduced the top end of its adjusted Ebitda forecast for the full year. Madison Muller reports on "Bloomberg The Close."

Hims faces restructuring charges as it shifts its U.S. weight-loss business away from compounded GLP-1 medications.

Investing.com -- Hims & Hers Health reported a wider-than-expected second-quarter loss on Monday, sending its shares down 1.5%.

Telehealth company Hims & Hers Health (NYSE:HIMS) reported revenue ahead of Wall Street’s expectations in Q2 CY2026, with sales up 38.2% year on year to $753.2 million. On top of that, next quarter’s revenue guidance ($890 million at the midpoint) was surprisingly good and 12.4% above what analysts were expecting. Its GAAP loss of $0.37 per share was significantly below analysts’ consensus estimates.

Hims & Hers Health (NYSE:HIMS) has issued a public response to a Federal Trade Commission lawsuit that challenges aspects of its telehealth practices and use of patient data. The company addressed the FTC action by outlining its position on how it handles telehealth consultations and consumer information, aiming to reassure users and investors. The lawsuit raises questions about regulatory risk for telehealth providers and how patient data is collected, stored, and used across the...

Small-cap stocks in the Russell 2000 (^RUT) can be a goldmine for investors looking beyond the usual large-cap names. But with less stability and fewer resources than their bigger counterparts, these companies face steeper challenges in scaling their businesses.

Hims & Hers shares crashed yesterday as the FTC filed a lawsuit against the telehealth provider. Here’s how you should play HIMS stock at current levels.

The FTC has filed a lawsuit against Hims & Hers Health alleging improper sharing of sensitive health data with advertising platforms and deceptive billing practices. Hims & Hers Health has publicly rejected the allegations and issued a formal response defending its data and billing practices. This action represents a new phase of regulatory scrutiny for NYSE:HIMS that investors are assessing alongside the company’s broader telehealth business. Hims & Hers Health, traded on the NYSE under...

The telehealth provider shared patient health information with Snap and Meta, a federal complaint says.

In the most recent trading session, Hims & Hers Health, Inc. (HIMS) closed at $29.32, indicating a -3.04% shift from the previous trading day.

Hims & Hers Health, Inc. (HIMS) closed the most recent trading day at $31.68, moving 3.21% from the previous trading session.

Hims & Hers Health shares have surged 45% in 30 days on GLP-1 coverage shifts, but overbought technicals, a Hold rating, and rising short interest suggest a pullback may be near.

In the most recent trading session, Hims & Hers Health, Inc. (HIMS) closed at $33.39, indicating a -1.62% shift from the previous trading day.

Hims & Hers Health, Inc. (HIMS) closed the most recent trading day at $31.89, moving +1.33% from the previous trading session.

Hims & Hers plunged 23% after a major Q1 earnings miss, but long-term growth stays intact via its Novo Nordisk GLP-1 partnership and a late 2026 expansion.

Company says proceeds will support expansion and technology investments

Hims & Hers Tumbles as Convertible Note Deal Sparks Dilution Fears

The S&P 500 Index ($SPX ) (SPY ) today is up +0.07%, the Dow Jones Industrial Average ($DOWI ) (DIA ) is up +0.29%, and the Nasdaq 100 Index ($IUXX ) (QQQ ) is down -0.25%. June E-mini S&P futures (ESM26 ) are up +0.10%, and June E-mini Nasdaq futures...

Hims & Hers (NYSE:HIMS) is dominating headlines this week because the GLP-1 darling just delivered one of the ugliest quarters in the telehealth sector’s short history, and bargain hunters are circling the wreckage. But here’s what you should actually be watching. The Q1 2026 release on May 11, 2026 was a fracture. EPS came in ... Forget Hims. Its CEO Dumped 436,000 Shares Before a 1,266% Earnings Miss. Here Is the Profitable Healthcare Stock to Own Instead